IP Library Granted Patent US 11,420,797
Granted Patent B2
US 11,420,797 · App. 15/788,614 · Granted Aug 23, 2022

Container closure and related methods

Inventors: Rainer Gerberzahn (Juechen, DE); Mark C. Mikol (Phoenix, AZ); Carsten Bertram (Scottsdale, AZ); Bernhard Orlich (Duesseldorf, DE)
Assignee: Henkel AG & Co. KGaA
B65D41/26B65D41/04B65D51/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,420,797
App. No.
15/788,614
Granted
Aug 23, 2022
Kind
B2
Abstract

A container closure includes a dosage body including at least one peripheral wall defining a containment chamber. The peripheral wall has an internal wall surface adjacent the containment chamber, the internal wall surface having a surface luminance. Indicia is carried by the internal wall surface, the indicia having an indicia luminance. A contrast between the surface luminance and the indicia luminance is at least about 0.67% on the Weber scale.

Claims (26)

1. A container closure, comprising:

a dosage body including at least one peripheral wall defining a containment chamber, the peripheral wall having an internal wall surface adjacent the containment chamber, the internal wall surface having a surface luminance; and

indicia, carried by the internal wall surface, the indicia having an indicia luminance that is lower than the surface luminance, a contrast between the surface luminance and the indicia luminance being at least about 0.67% on the Weber scale.

2. The closure of claim 1 , wherein the contrast between the surface luminance and the indicia luminance is at least about 20% on the Weber scale.

3. The closure of claim 1 , wherein the contrast between the surface luminance and the indicia luminance is at least about 50% on the Weber scale.

4. The closure of claim 1 , wherein the indicia comprises printed indicia.

5. The closure of claim 4 , wherein the printed indicia includes an indicia height, the indicia height being less than about 40 μm.

6. The closure of claim 4 , further comprising a printed substrate carried by the internal wall surface, the indicia being printed on the printed substrate.

7. The closure of claim 6 , wherein the printed substrate comprises an in-mold label formed at least partially in the internal wall surface.

8. A container closure, comprising:

a dosage body including at least one peripheral wall defining a containment chamber, the peripheral wall having an internal wall surface adjacent the containment chamber, the internal wall surface having a surface luminance;

indicia, carried by the internal wall surface, the indicia comprising printed indicia and having an indicia luminance that is lower than the surface luminance, a contrast between the surface luminance and the indicia luminance being at least about 0.67% on the Weber scale.

9. The closure of claim 8 , wherein the printed indicia includes an indicia height, the indicia height being less than about 40 μm.

10. The closure of claim 8 , further comprising a printed substrate carried by the internal wall surface, the printed indicia being printed on the printed substrate.

11. The closure of claim 10 , wherein the printed substrate comprises an in-mold label at least partially formed in the internal wall surface.

12. The closure of claim 10 , wherein the printed substrate comprises a label adhered to the internal wall surface.

13. The closure of claim 8 , wherein the printed indicia is printed directly on the internal wall surface.

14. A method of forming a container closure, comprising:

forming a dosage body having at least one peripheral wall defining a containment chamber, the peripheral wall having an internal wall surface adjacent the containment chamber, the internal wall surface having a surface luminance; and

applying indicia to the internal wall surface, the indicia being printed indicia having an indicia luminance that is lower than the surface luminance;

selecting the surface luminance and the indicia luminance such that a contrast between the surface luminance and the indicia luminance is at least about 0.67% on the Weber scale.

15. The method of claim 14 , wherein applying the indicia to the internal wall surface comprises applying a printed substrate to the internal wall surface, the printed indicia being printed on the printed substrate.

16. The method of claim 15 , wherein the printed substrate comprises an in-mold label, and wherein forming the dosage body includes forming the in-mold label at least partially within the internal wall surface.

17. The method of claim 15 , wherein the printed substrate comprises a label, and wherein applying the indicia to the internal wall surface comprises adhering the label to the internal wall surface.

18. The method of claim 14 , wherein the contrast between the surface luminance and the indicia luminance is at least about 20% on the Weber scale.

19. The method of claim 14 , wherein applying the printed indicia to the internal wall surface includes printing the printed indicia directly on the internal wall surface.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2022
From: HENKEL IP & HOLDING GMBH
To: HENKEL AG & CO. KGAA
Reel/Frame 059207/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2018
From: GEBERZAHN, RAINER; MIKO, MARK CHARLES; BERTRAM, CARSTEN; ORLICH, BERNHARD
To: HENKEL AG & CO. KGAA; HENKEL IP & HOLDING GMBH
Reel/Frame 046779/0387 →
Continuity (1)
Related Publication 20190119007A1 · Apr 25, 2019